Reuters logo
BRIEF-Amarin up 20.1 percent premarket; FDA delays decision on wider use approval for vascepa drug
December 20, 2013 / 1:05 PM / 4 years ago

BRIEF-Amarin up 20.1 percent premarket; FDA delays decision on wider use approval for vascepa drug

NEW YORK, Dec 20 (Reuters) - Amarin Corporation PLC : * Amarin Corp up 20.1 percent to $1.91 in premarket; FDA delays decision on wider use approval for vascepa drug

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below